The intracranial hemorrhage developed in 3.9% (n = 3) of all patients: 3.4% (n = 1/29) of UFH-treated and 7.4% (n = 2/27) of t-PA-treated patients. This evidence concerns the gene PLAT and intracranial hemorrhage.